The effect of chronic kidney disease on lipid metabolism

The major cause of death among chronic kidney disease patients is cardiovascular diseases. Cardiovascular and kidney disease are interrelated and increase the severity of each other. Dyslipidemia is one the major causes of cardiovascular disease among chronic kidney disease patients along with diabe...

Full description

Saved in:
Bibliographic Details
Published in:International urology and nephrology 2019-02, Vol.51 (2), p.265-277
Main Authors: Dincer, Neris, Dagel, Tuncay, Afsar, Baris, Covic, Adrian, Ortiz, Alberto, Kanbay, Mehmet
Format: Article
Language:English
Subjects:
Cardiovascular diseases
Cardiovascular Diseases - metabolism
Cardiovascular Diseases - prevention & control
Diabetes mellitus
Dyslipidemia
Dyslipidemias - etiology
Dyslipidemias - metabolism
Humans
Kidney diseases
Kidneys
Lipid Metabolism
Lipoproteins
Low density lipoprotein
Medicine
Medicine & Public Health
Metabolic disorders
Nephrology
Nephrology - Review
Patients
Renal Insufficiency, Chronic - complications
Renal Insufficiency, Chronic - metabolism
Risk Factors
Statins
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The major cause of death among chronic kidney disease patients is cardiovascular diseases. Cardiovascular and kidney disease are interrelated and increase the severity of each other. Dyslipidemia is one the major causes of cardiovascular disease among chronic kidney disease patients along with diabetes and hypertension. The relationship between dyslipidemia and chronic kidney disease is reciprocal. Dyslipidemia is known to be a risk factor for chronic kidney disease and chronic kidney disease causes major alterations on lipoprotein profile, defined as the “dyslipidemic profile” of chronic kidney disease patients. Increased triglyceride, very low density lipoprotein and oxidized low density lipoprotein as well as decreased high density lipoprotein and changes in the composition of lipoproteins contribute to the “dyslipidemic profile.” Treatment strategies targeting the “dyslipidemic profile” of chronic kidney disease could contribute to prevent cardiovascular diseases. Current therapy is based on the patient kidney function and consist mainly of statins. This review focuses on the effects of chronic kidney disease on the lipoprotein profile and how this may impact novel therapeutic approaches to cardiovascular risk.
ISSN:0301-1623
1573-2584
DOI:10.1007/s11255-018-2047-y